Skip to main content
Erschienen in: International Cancer Conference Journal 4/2017

03.08.2017 | Case report

A case of ovarian growing teratoma syndrome treated by cytoreductive surgery

verfasst von: Yuko Goto, Akiyoshi Mizumoto, Masamitsu Hirano, Nobuyuki Takao, Masumi Ichinose, Kousuke Noguchi, Ippei Kasyu, Mitsuaki Ishida, Yutaka Yonemura

Erschienen in: International Cancer Conference Journal | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Ovarian growing teratoma syndrome (GTS) is a rare disease characterized by growth of a benign tumor during or after chemotherapy, following the removal of germ cell gonadal cancers. Although benign, GTS tumors grow gradually and may compress surrounding organs. In addition, up to 3% of GTS cases can undergo malignant transformation. It is, therefore, needed to treat GTS. No standardized management protocol has been established to treat GTS; however, surgical resection is likely the only effective treatment because tumors in GTS are resistant to chemotherapy and radiation therapy. However, complete resection with conventional procedures is sometimes difficult when peritoneal metastasis is widespread. We report a rare case of ovarian GTS with widespread peritoneal metastases, which was totally resected by peritonectomy procedures. A 45-year-old Japanese woman was initially diagnosed with an immature teratoma grade 3, which was treated by hysterectomy and bilateral salpingo-oophorectomy. Adjuvant chemotherapy was performed after surgery with bleomycin, etoposide, cisplatin, and other chemotherapies. Due to recurrence of a chemoresistant tumor and normalization of tumor markers, GTS was suspected. She was referred to our institute, and complete cytoreductive surgery was performed using peritonectomy procedures, including parietal peritoneal resection, greater omentectomy, lesser omentectomy, rectosigmoid colectomy, diaphragm dissection, and cholecystectomy. A complete cytoreduction with no visible residual tumor tissue was achieved.
Literatur
2.
Zurück zum Zitat André F, Fizazi K, Culine S et al (2000) The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer Oxf Engl 1990 36:1389–1394 André F, Fizazi K, Culine S et al (2000) The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer Oxf Engl 1990 36:1389–1394
4.
Zurück zum Zitat DiSaia PJ, Saltz A, Kagan AR, Morrow CP (1977) Chemotherapeutic retroconversion of immature teratoma of the ovary. Obstet Gynecol 49:346–350PubMed DiSaia PJ, Saltz A, Kagan AR, Morrow CP (1977) Chemotherapeutic retroconversion of immature teratoma of the ovary. Obstet Gynecol 49:346–350PubMed
6.
Zurück zum Zitat Hong WK, Wittes RE, Hajdu ST et al (1977) The evolution of mature teratoma from malignant testicular tumors. Cancer 40:2987–2992CrossRefPubMed Hong WK, Wittes RE, Hajdu ST et al (1977) The evolution of mature teratoma from malignant testicular tumors. Cancer 40:2987–2992CrossRefPubMed
9.
Zurück zum Zitat Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 249:900–907. doi:10.1097/SLA.0b013e3181a45d86 CrossRefPubMed Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 249:900–907. doi:10.​1097/​SLA.​0b013e3181a45d86​ CrossRefPubMed
10.
Zurück zum Zitat Mizumoto A, Canbay E, Hirano M et al (2012) Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan. Gastroenterol Res Pract. doi:10.1155/2012/836425 Mizumoto A, Canbay E, Hirano M et al (2012) Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan. Gastroenterol Res Pract. doi:10.​1155/​2012/​836425
13.
Zurück zum Zitat Yuen PM, Yu KM, Yip SK et al (1997) A randomized prospective study of laparoscopy and laparotomy in the management of benign ovarian masses. Am J Obstet Gynecol 177:109–114CrossRefPubMed Yuen PM, Yu KM, Yip SK et al (1997) A randomized prospective study of laparoscopy and laparotomy in the management of benign ovarian masses. Am J Obstet Gynecol 177:109–114CrossRefPubMed
14.
Zurück zum Zitat Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society of Reproductive Surgeons (2013) Pathogenesis, consequences, and control of peritoneal adhesions in gynecologic surgery: a committee opinion. Fertil Steril 99:1550–1555. doi:10.1016/j.fertnstert.2013.02.031 CrossRef Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society of Reproductive Surgeons (2013) Pathogenesis, consequences, and control of peritoneal adhesions in gynecologic surgery: a committee opinion. Fertil Steril 99:1550–1555. doi:10.​1016/​j.​fertnstert.​2013.​02.​031 CrossRef
16.
Zurück zum Zitat Bentivegna E, Azaïs H, Uzan C et al (2015) Surgical outcomes after debulking surgery for intraabdominal ovarian growing teratoma syndrome: analysis of 38 cases. Ann Surg Oncol 22(Suppl 3):S964–S970. doi:10.1245/s10434-015-4608-y CrossRefPubMed Bentivegna E, Azaïs H, Uzan C et al (2015) Surgical outcomes after debulking surgery for intraabdominal ovarian growing teratoma syndrome: analysis of 38 cases. Ann Surg Oncol 22(Suppl 3):S964–S970. doi:10.​1245/​s10434-015-4608-y CrossRefPubMed
Metadaten
Titel
A case of ovarian growing teratoma syndrome treated by cytoreductive surgery
verfasst von
Yuko Goto
Akiyoshi Mizumoto
Masamitsu Hirano
Nobuyuki Takao
Masumi Ichinose
Kousuke Noguchi
Ippei Kasyu
Mitsuaki Ishida
Yutaka Yonemura
Publikationsdatum
03.08.2017
Verlag
Springer Japan
Erschienen in
International Cancer Conference Journal / Ausgabe 4/2017
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-017-0304-z

Weitere Artikel der Ausgabe 4/2017

International Cancer Conference Journal 4/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.